Korean J Med.  2016 Apr;90(4):357-360. 10.3904/kjm.2016.90.4.357.

Good Response of a Salivary Duct Carcinoma to Androgen Deprivation Therapy

• Lee JM
• Lee JA
• Lim SY
• Kim SM
• Lee YH
• Yoon JG
• Kang EJ

• KMID: 2268852
• DOI: http://doi.org/10.3904/kjm.2016.90.4.357

Abstract

Salivary duct carcinoma (SDC) is a rare, aggressive tumor. Androgen deprivation therapy (ADT) has been shown to have beneficial effects on SDC-expressing androgen receptors (ARs). A 69-year-old male with a right neck mass presented to our clinic. Computed tomography (CT) of the neck revealed a mass (6 cm diameter) on the right parotid gland, and enlarged lymph nodes. Examination of a needle biopsy sample identified SDC-expressing ARs. We performed total parotidectomy with bilateral neck dissection and concurrent postoperative chemoradiotherapy (total 66 Gy) with cisplatin (35 mg/m2), followed by another two cycles of chemotherapy (cisplatin 60 mg/m2, 5 FU 750 mg/m2). Post-treatment neck CT indicated that no residual tumor tissue remained; however, chest CT indicated recurrence in the right axilla. We initiated ADT with bicalutamide and leuprolide. Five months later, the axillar tumor tissue had almost disappeared. Our case demonstrates that ADT is effective for SDC of ARs. Therefore, clinicians should consider ADT in recurrent or metastatic SDC of ARs.

Keyword

Androgen receptor antagonist; Salivary gland cancer; Androgen receptors

MeSH Terms

Aged
Axilla
Biopsy, Needle
Chemoradiotherapy
Cisplatin
Drug Therapy
Humans
Leuprolide
Lymph Nodes
Male
Neck
Neck Dissection
Neoplasm, Residual
Parotid Gland
Receptors, Androgen
Recurrence
Salivary Ducts*
Salivary Gland Neoplasms
Tomography, X-Ray Computed
Cisplatin
Leuprolide
Receptors, Androgen